Cargando…

The Changing Face of Cystic Fibrosis and Its Implications for Screening

Early diagnosis, multidisciplinary care, and optimized and preventive treatments have changed the face of cystic fibrosis. Life expectancy has been expanded in the last decades. Formerly a pediatric disease, cystic fibrosis has reached adulthood. Mutation-specific treatments will expand treatment op...

Descripción completa

Detalles Bibliográficos
Autor principal: Naehrlich, Lutz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570194/
https://www.ncbi.nlm.nih.gov/pubmed/33123635
http://dx.doi.org/10.3390/ijns6030054
_version_ 1783596892851011584
author Naehrlich, Lutz
author_facet Naehrlich, Lutz
author_sort Naehrlich, Lutz
collection PubMed
description Early diagnosis, multidisciplinary care, and optimized and preventive treatments have changed the face of cystic fibrosis. Life expectancy has been expanded in the last decades. Formerly a pediatric disease, cystic fibrosis has reached adulthood. Mutation-specific treatments will expand treatment options and give hope for further improvement of quality of life and life expectancy. Newborn screening for CF fits perfectly into these care structures and offers the possibility of preventive treatment even before symptoms occur. Especially in countries without screening, newborn screening will fulfill that promise only with increased awareness and new care structures.
format Online
Article
Text
id pubmed-7570194
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75701942020-10-28 The Changing Face of Cystic Fibrosis and Its Implications for Screening Naehrlich, Lutz Int J Neonatal Screen Review Early diagnosis, multidisciplinary care, and optimized and preventive treatments have changed the face of cystic fibrosis. Life expectancy has been expanded in the last decades. Formerly a pediatric disease, cystic fibrosis has reached adulthood. Mutation-specific treatments will expand treatment options and give hope for further improvement of quality of life and life expectancy. Newborn screening for CF fits perfectly into these care structures and offers the possibility of preventive treatment even before symptoms occur. Especially in countries without screening, newborn screening will fulfill that promise only with increased awareness and new care structures. MDPI 2020-07-03 /pmc/articles/PMC7570194/ /pubmed/33123635 http://dx.doi.org/10.3390/ijns6030054 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Naehrlich, Lutz
The Changing Face of Cystic Fibrosis and Its Implications for Screening
title The Changing Face of Cystic Fibrosis and Its Implications for Screening
title_full The Changing Face of Cystic Fibrosis and Its Implications for Screening
title_fullStr The Changing Face of Cystic Fibrosis and Its Implications for Screening
title_full_unstemmed The Changing Face of Cystic Fibrosis and Its Implications for Screening
title_short The Changing Face of Cystic Fibrosis and Its Implications for Screening
title_sort changing face of cystic fibrosis and its implications for screening
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570194/
https://www.ncbi.nlm.nih.gov/pubmed/33123635
http://dx.doi.org/10.3390/ijns6030054
work_keys_str_mv AT naehrlichlutz thechangingfaceofcysticfibrosisanditsimplicationsforscreening
AT naehrlichlutz changingfaceofcysticfibrosisanditsimplicationsforscreening